Related Experiment Video
Updated: Aug 21, 2026
Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
Impact of E1a modifications on tumor-selective adenoviral replication and toxicity
Harald Sauthoff1, Teona Pipiya, Sheila Heitner
1Division of Pulmonary & Critical Care Medicine, New York University School of Medicine, New York, NY 10016, USA.
Abstract:
Replicating adenoviral vectors are capable of multiplying up to a thousandfold in the target cell, a property that might prove to be of tremendous potential for cancer therapy. However, restricting viral replication and toxicity to cancer cells is essential to optimize safety. It has been proposed that modifications of the E1a protein that impair binding to Rb or p300 will prevent S-phase induction in normal cells, resulting in selective viral replication in tumor cells. However, it remains uncertain which of the several possible E1a modifications would be most effective at protecting normal cells without compromising the oncolytic effect of the vector. In this study, we have expressed several E1a-deletion mutants at high levels using the CMV promoter and tested them for their ability to facilitate S-phase induction, viral replication, and cytotoxicity in both normal and cancer cells. Deletion of the Rb-binding domain within E1a only slightly decreased the ability of the virus to induce S phase in growth-arrested cells. The effect of this deletion on viral replication and cytotoxicity was variable. There was reduced cytotoxicity in normal bronchial epithelial cells; however, in some normal cell types there was equal viral replication and cytotoxicity compared with wild type. Deletions in both the N-terminus and the Rb-binding domain were required to block S-phase induction effectively in growth-arrested normal cells; in addition, this virus demonstrated reduced viral replication and cytotoxicity in normal cells. An equally favorable replication and cytotoxicity profile was induced by a virus expressing E1a that is incapable of binding to the transcriptional adapter motif (TRAM) of p300. All viruses were equally cytotoxic to cancer cells compared with wild-type virus. In conclusion, deletion of the Rb-binding site alone within E1a may not be the most efficacious means of targeting viral replication and toxicity. However, deletion within the N-terminus in conjunction with a deletion within the Rb-binding domain, or deletion of the p300-TRAM binding domain, induces a more favorable cytotoxicity profile.
Insights
Modifying adenoviral vectors for cancer therapy requires selective replication in tumors. Deleting Rb-binding sites alone is insufficient; combined N-terminus and Rb-binding domain deletions, or p300-TRAM binding domain deletion, improve safety without harming cancer cell cytotoxicity.
Area of Science:
- Oncolytic virotherapy
- Molecular virology
- Cancer gene therapy
Background:
- Replicating adenoviral vectors show promise for cancer therapy due to significant replication in target cells.
- Ensuring selective viral replication and toxicity in cancer cells is crucial for patient safety.
- Modifications to the E1a protein, specifically targeting Rb or p300 binding, are proposed to achieve tumor selectivity.
Purpose of the Study:
- To evaluate the efficacy of various E1a-deletion mutants in controlling viral replication and cytotoxicity in normal versus cancer cells.
- To identify specific E1a modifications that enhance safety by preventing S-phase induction in normal cells while maintaining oncolytic potential.
- To determine the most effective strategy for selective viral targeting in cancer therapy.
Main Methods:
- Expression of E1a-deletion mutants using the CMV promoter.
- Assessment of S-phase induction in growth-arrested cells.
- Measurement of viral replication and cytotoxicity in both normal and cancer cell lines.
Main Results:
- Deletion of the Rb-binding domain alone had minimal impact on S-phase induction and variable effects on replication and cytotoxicity in normal cells.
- Combined deletions in the N-terminus and Rb-binding domain effectively blocked S-phase induction in normal cells, reducing viral replication and toxicity.
- Disrupting the p300-TRAM binding domain also yielded a favorable replication and cytotoxicity profile in normal cells.
- All tested viral vectors maintained equal cytotoxicity against cancer cells compared to wild-type virus.
Conclusions:
- Sole deletion of the E1a Rb-binding site is not sufficient for effective targeting of viral replication and toxicity.
- Modifications involving N-terminus and Rb-binding domain deletions, or p300-TRAM binding domain deletion, offer improved safety profiles for oncolytic adenoviral vectors.
- These targeted modifications enhance selectivity, reducing risks to normal tissues while preserving therapeutic efficacy against tumors.
More Related Videos
13:54Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death
Published on: October 21, 2012
10:22Isolation of Viral Replication Compartment-enriched Sub-nuclear Fractions from Adenovirus-infected Normal Human Cells
Published on: November 12, 2015
